EP
AUPH icon

Eudaimonia Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Eudaimonia Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000
Closed -$13K – 448
2021
Q1 		$13K Buy
+1,000
New +$14.5K ﹤0.01% 1090

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eudaimonia Partners's AUPH Position: Q2 2021 in Review

Eudaimonia Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2021, closing a stake of 1,000 shares — an estimated $13K sold.

Eudaimonia Partners first reported a position in AUPH in Q1 2021 and held it in 1 quarter. The position peaked at $13K in Q1 2021. 167 funds tracked by Wall St. Rank hold AUPH as of Q2 2021.

  • Eudaimonia Partners reported no remaining Aurinia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 1,000 Aurinia Pharmaceuticals shares in Q2 2021, an estimated $13K.
  • Eudaimonia Partners first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Aurinia Pharmaceuticals position peaked at $13K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.